Sathekge, Mike MachabaBruchertseifer, FrankVorster, MarizaLawal, Ismaheel OpeyemiKnoesen, OttoMahapane, JohncyDavis, CindyMdlophane, AmandaMaes, AlexMokoala, Kgomotso M.G.Mathabe, KgomotsoVan de Wiele, ChristopheMorgenstern, Alfred2023-07-262023-07-262022-10Sathekge, M., Bruchertseifer, F., Vorster, M., Lawal, I.O., Knoesen, O., Mahapane, J., Davis, C., Mdlophane, A., Maes, A., Mokoala, K., Mathabe, K., Van de Wiele, C. & Morgenstern, A. 2022, 'mCRPC patients receiving 225Ac-PSMA-617 therapy in the post-androgen deprivation therapy setting: response to treatment and survival analysis', Journal of Nuclear Medicine, vol. 63, no. 10, pp. 1496-1502, doi : 10.2967/jnumed.121.263618.0161-5505 (print)2159-662X (online)10.2967/jnumed.121.263618http://hdl.handle.net/2263/91638Please read abstract in the article.en© 2022 by the Society of Nuclear Medicine and Molecular Imaging. Immediate Open Access: Creative Commons Attribution 4.0 International License (CC BY).225Ac-PSMA-617Prostate specific membrane antigen (PSMA)Metastatic castration-resistant prostate cancer (mCRPC)Androgen deprivation treatment (ADT)Therapy responsePSA responseProstate carcinomaProstate specific antigen (PSA)SDG-03: Good health and well-beingArticle